FNY Partners Fund’s Achillion Pharmaceuticals ACHN Stock Holding History

FNY Partners Fund’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-9,015	Closed	-$37K	–	1347
2017 Q1	$37K	Buy	+9,015	New	+$37.4K	﹤0.01%	806

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

FNY Partners Fund's ACHN Position: Q2 2017 in Review

FNY Partners Fund sold out of Achillion Pharmaceuticals (ACHN) in Q2 2017, closing a stake of 9,015 shares — an estimated $37K sold.

FNY Partners Fund first reported a position in ACHN in Q1 2017 and held it in 1 quarter. The position peaked at $37K in Q1 2017. 129 funds tracked by Wall St. Rank hold ACHN as of Q2 2017.

FNY Partners Fund reported no remaining Achillion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
FNY Partners Fund sold 9,015 Achillion Pharmaceuticals shares in Q2 2017, an estimated $37K.
FNY Partners Fund first reported a position in Achillion Pharmaceuticals in Q1 2017 and held it in 1 quarter.
FNY Partners Fund's Achillion Pharmaceuticals position peaked at $37K in Q1 2017.
129 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.